Articles Tập 67 Số CĐ1-NCKH 27/01/2026

EVALUATION OF INTERLEUKIN-6, TNF-ALPHA, AND TGF-BETA LEVELS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

Ha Le Thuy1,2, Toan Nguyen Linh3,4, Hung Ta Viet1,2, Xuan Nguyen Thi5,6
1 Military Hospital 103, Military Medical Academy
2 Bệnh viện Quân y 103, Học Viện Quân y
3 Department of Pathophysiology, Military Medical Academy
4 Bộ môn Sinh lý bệnh, Học Viện Quân y
5 Institute of Biology, Vietnam Academy of Science and Technology
6 Viện Sinh học, Viện Hàn lâm Khoa học và Công nghệ Việt Nam
DOI: 10.52163/yhc.v67iCD1.4292
77 Views
50 Downloads
Abstract

Objective: To determine plasma levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and transforming growth factor-beta (TGF-β), and to investigate their associations with selected laboratory parameters in patients with chronic lymphocytic leukemia (CLL).

Methods: A cross-sectional descriptive study was conducted in 50 patients with CLL from March 2022 to September 2023 at the National Institute of Hematology and Blood Transfusion. Plasma concentrations of IL-6, TNF-α, and TGF-β were quantified using the sandwich enzyme-linked immunosorbent assay (ELISA) method.

Results: The median plasma concentrations of IL-6, TNF-α, and TGF-β were 5.63 pg/mL, 0.88 pg/mL, and 534.53 pg/mL, respectively. IL-6 levels differed significantly among risk groups (p < 0.05). Plasma IL-6 was negatively correlated with hemoglobin concentration (r = −0.288; p = 0.043) and hematocrit (r = −0.304; p = 0.032). Plasma TGF-β levels showed positive correlations with red blood cell count (r = 0.407; p = 0.003), hemoglobin (r = 0.428; p = 0.002), and hematocrit (r = 0.417; p = 0.003).

Conclusion: The median plasma concentrations of IL-6, TNF-α, and TGF-β were 5.63 pg/mL, 0.884 pg/mL, and 534.53 pg/mL, respectively. IL-6 and TGF-β may play a role in altering selected hematological parameters and glucose levels in patients with CLL.

Keywords
Interleukin 6, TNF-alpha, TGF-beta, chronic lymphocytic leukemia (CLL).
References
[1]
Cronin KA, Ries LA, Edwards BK (2014). The surveillance, epidemiology, and end results (SEER) program of the National Cancer Institute. Cancer, 120, 3755-3757. Google Scholar
[2]
Hassan EA, Abdelhady EA, Abdelsamee HF, El-Razzaz MK (2024). Serum Interleukin 6 (IL-6) as Prognostic Marker in Egyptian CLL patients. International Journal of Hematology-Oncology Stem Cell Research, 18 (2), 140. Google Scholar
[3]
Ayoub M, Susin SA, Bauvois B (2024). Tumor Cell Survival Factors and Angiogenesis in Chronic Lymphocytic Leukemia: How Hot Is the Link? Cancers, 17 (1), 72. Google Scholar
[4]
Marquez ME, Sernbo S, Payque E, et al (2022). TGF-β/SMAD pathway is modulated by miR-26b-5p: Another piece in the puzzle of chronic lymphocytic leukemia progression. Cancers, 14 (7), 1676. Google Scholar
[5]
Hà TTTT, Huân TPC, Huệ TĐT, et al (2022). Hướng dẫn chẩn đoán và điều trị một số bệnh lý huyết học. Bộ Y tế, Google Scholar
[6]
Mousa MA-E-HA-E-R, Eweis IEI, Ahmed SS, Gaafar AM (2022). Assessment of IL6 and TNF α in chronic lymphocytic leukemia. International Journal of Medical Arts, 4 (10), 2725-2733. Google Scholar
[7]
Ferrajoli A, Keating MJ, Manshouri T, et al (2002). The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia. Blood, The Journal of the American Society of Hematology, 100 (4), 1215-1219. Google Scholar
[8]
Maltezas D, Sarris K, Koulieris E, et al (2012). Increased serum transforming growth factor-beta1 (Tgf-beta1) is related to a better outcome in MM, WM and CLL patients. Blood advances, 120 (21), 4976. Google Scholar
[9]
Gora-Tybor J, Blonski JZ, Robak T (2003). Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia. Mediators of Inflammation, 12 (3), 167-171. Google Scholar
[10]
Areström I, Zuber B, Bengtsson T, Ahlborg N (2012). Measurement of human latent transforming growth factor-β1 using a latency associated protein-reactive ELISA. Journal of Immunological Methods, 379 (1-2), 23-29. Google Scholar
[11]
DeCoteau JF, Knaus PI, Yankelev H, et al (1997). Loss of functional cell surface transforming growth factor β (TGF-β) type 1 receptor correlates with insensitivity to TGF-β in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences, 94 (11), 5877-5881. Google Scholar